Draft:Ajay Vishwakarma 2
| Submission declined on 9 September 2024 by Utopes (talk). This submission is not adequately supported by reliable sources. Reliable sources are required so that information can be verified. If you need help with referencing, please see Referencing for beginners and Citing sources. This submission does not appear to be written in the formal tone expected of an encyclopedia article. Entries should be written from a neutral point of view, and should refer to a range of independent, reliable, published sources. Please rewrite your submission in a more encyclopedic format. Please make sure to avoid peacock terms that promote the subject.
Where to get help
How to improve a draft
You can also browse Wikipedia:Featured articles and Wikipedia:Good articles to find examples of Wikipedia's best writing on topics similar to your proposed article. Improving your odds of a speedy review To improve your odds of a faster review, tag your draft with relevant WikiProject tags using the button below. This will let reviewers know a new draft has been submitted in their area of interest. For instance, if you wrote about a female astronomer, you would want to add the Biography, Astronomy, and Women scientists tags. Editor resources
|  |
Comment: Articles written by the subject are rarely useful references, and cannot establish the subject's notability as secondary, independent sources are required for this. If this is an WP:AUTOBIO, please disclose a WP:COI. Utopes (talk / cont) 05:33, 9 September 2024 (UTC)
Ajay Vishwakarma
[edit]Ajay Vishwakarma is a biotechnology entrepreneur and founder and CEO of Cell BioEngines, Inc.[1][2][3]. He is an internationally recognized expert in stem cell and tissue engineering and has made several original contributions that have influenced this field. Additionally, he is an Adjunct Professor of Translational Biotechnology at Johns Hopkins University.
Early life and education
[edit]Born in Bombay, Ajay graduated with a doctor's degree in dental medicine at Maharashtra University of Health Sciences. Ajay graduated with a master's degree in tissue engineering and regenerative medicine from Cardiff University in 2011. He performed his post-doctoral work in immune-engineering at Harvard Medical School and Massachusetts Institute of Technology.
As a 22-year old, Ajay served as a volume editor for two authoritative publications[4][5] in his field by Academic Press (an imprint of Elsevier, one of the world's largest publishing houses for academic and scientific literature) with a foreword by Robert S. Langer (co-founder of Moderna) and Hans Clevers (head of pRED of Roche). He later joined Harvard University, MGH Cancer Center and Broad Institute to study doctorate in cancer immunology but dropped out to establish Cell BioEngines during COVID-19 pandemic.
Career
[edit]Vishwakarma moved from the UK to Boston in 2014. Vishwakarma and colleagues developed biomaterials for controlling the behavior of human immune cells at Harvard University and Massachusetts Institute of Technology. They demonstrated how micro- and nano-scale technologies could be used to design cell-instructive immunomodulatory biomaterials that are able to control the behavior of immune cells - in particular of macrophages, a type of immune cell that are integral to body's identification and destruction of bacteria and other organisms that are 'harmful'[6][7]. They embedded M2-type macrophages, and stem cells to enhance bone repair[8]. During his PhD, Vishwakarma discovered unique functional immune cell genomic signatures directly in renal cancer patient tumors with colleagues at Harvard Medical School and Carver College of Medicine that led to identification of several possible treatment targets for solid cancers[9][10]. The discovery advanced the field several steps in this regard. Additionally, his seminal work on TANK-Binding Kinase 1 (TBK1) led to the discovery of TBK1 as a novel cancer immunotherapy target[11][12]
Cell BioEngines was established to leverage Vishwakarma's expertise in, and achievements toward use of single-cell genomic strategies that identified rare immune cell-subtypes including cDC1 dendritic cells, Natural Killer memory cells and Ki67+ T cells in human cancer patients, understand their function using ex vivo patient-derived organoid models, and to further develop scalable manufacturing technologies to mass produce them from stem cells for therapeutic use. It is backed by SOSV[13] and named as one of the 2024 SOSV Human Health 100 most exciting companies in the SOSV portfolio transforming human health through deep tech innovations[14]. As Chief Executive Officer, Vishwakarma leverages his expertise in stem cell and tissue engineering therapy to execute an ambitious growth strategy for the company.
References
[edit]- ^ "Cell BioEngines Enters into an Exclusive Worldwide Agreement to Develop and Commercialize Potent Immune Cell States to Cure Cancer". Yahoo Finance. 2023-01-26. Retrieved 2024-09-09.
- ^ IndieBio (2023-09-13). Cell BioEngines Interview. Retrieved 2024-09-09 – via YouTube.
- ^ "Cell BioEngines Enters Agreement with Miltenyi Bioindustry to Manufacture Hematopoietic Cell Therapy Clinical Program". BioSpace. 2023-12-29. Retrieved 2024-09-09.
- ^ Vishwakarma, Ajaykumar; Karp, Jeffrey, eds. (2017). Biology and engineering of stem cell niches. London: Elsevier/Academic Press. ISBN 978-0-12-802734-9. OCLC 960895662.
- ^ Vishwakarma, Ajaykumar; Sharpe, Paul T.; Shi, Songtao; Ramalingam, Murugan (2015). Stem cell biology and tissue engineering in dental sciences. Amsterdam: Elsevier/Academic Press. ISBN 978-0-12-397157-9.
- ^ Vishwakarma, Ajaykumar; Bhise, Nupura S.; Evangelista, Marta B.; Rouwkema, Jeroen; Dokmeci, Mehmet R.; Ghaemmaghami, Amir M.; Vrana, Nihal Engin; Khademhosseini, Ali (June 2016). "Engineering Immunomodulatory Biomaterials To Tune the Inflammatory Response". Trends in Biotechnology. 34 (6): 470–482. doi:10.1016/j.tibtech.2016.03.009. PMID 27138899.
- ^ Alvarez, Mario Moisés; Liu, Julie C.; Trujillo-de Santiago, Grissel; Cha, Byung-Hyun; Vishwakarma, Ajaykumar; Ghaemmaghami, Amir M.; Khademhosseini, Ali (October 2016). "Delivery strategies to control inflammatory response: Modulating M1–M2 polarization in tissue engineering applications". Journal of Controlled Release. 240: 349–363. doi:10.1016/j.jconrel.2016.01.026. PMC 4945478. PMID 26778695.
- ^ "2015 4 th TERMIS World CongressBoston, MassachusettsSeptember 8–11, 2015". Tissue Engineering Part A. 21 (S1): S–1–S-413. September 2015. doi:10.1089/ten.tea.2015.5000.abstracts. ISSN 1937-3341. PMID 26317531.
- ^ Borcherding, Nicholas; Vishwakarma, Ajaykumar; Voigt, Andrew P.; Bellizzi, Andrew; Kaplan, Jacob; Nepple, Kenneth; Salem, Aliasger K.; Jenkins, Russell W.; Zakharia, Yousef; Zhang, Weizhou (2021-01-27). "Mapping the immune environment in clear cell renal carcinoma by single-cell genomics". Communications Biology. 4 (1): 122. doi:10.1038/s42003-020-01625-6. ISSN 2399-3642. PMC 7840906. PMID 33504936.
- ^ Kim, Myung-Chul; Borcherding, Nicholas; Ahmed, Kawther K.; Voigt, Andrew P.; Vishwakarma, Ajaykumar; Kolb, Ryan; Kluz, Paige N.; Pandey, Gaurav; De, Umasankar; Drashansky, Theodore; Helm, Eric Y.; Zhang, Xin; Gibson-Corley, Katherine N.; Klesney-Tait, Julia; Zhu, Yuwen (2021-10-01). "CD177 modulates the function and homeostasis of tumor-infiltrating regulatory T cells". Nature Communications. 12 (1): 5764. Bibcode:2021NatCo..12.5764K. doi:10.1038/s41467-021-26091-4. ISSN 2041-1723. PMC 8486774. PMID 34599187.
- ^ Vishwakarma, Ajaykumar; Sun, Yi; Fu, Amina; Robitschek, Emily; Iracheta-Vellve, Arvin; Stinson, Susanna; Salem, Aliasger; Manguso, Robert; Jenkins, Russell (2019-12-01). "Abstract B065: TANK-Binding Kinase 1 (TBK1) as a novel cancer immunotherapy target". Molecular Cancer Therapeutics. 18 (12_Supplement): B065. doi:10.1158/1535-7163.TARG-19-B065. ISSN 1535-7163.
- ^ Sun, Yi; Revach, Or-yam; Anderson, Seth; Kessler, Emily A.; Wolfe, Clara H.; Jenney, Anne; Mills, Caitlin E.; Robitschek, Emily J.; Davis, Thomas G. R.; Kim, Sarah; Fu, Amina; Ma, Xiang; Gwee, Jia; Tiwari, Payal; Du, Peter P. (2023-03-02). "Targeting TBK1 to overcome resistance to cancer immunotherapy". Nature. 615 (7950): 158–167. Bibcode:2023Natur.615..158S. doi:10.1038/s41586-023-05704-6. ISSN 0028-0836. PMC 10171827. PMID 36634707.
- ^ "SOSV-backed Biotech Firm Cell BioEngines Decides New York Is the Place to BeCell BioEngines, Inc moves to Manhattan, New York, to leverage the city's focus and strategic investment in biotech". BioSpace. 2024-01-13. Retrieved 2024-09-09.
- ^ Desmond, Ned (2024-03-12). "Announcing the 2024 Human Health 100". SOSV. Retrieved 2024-09-09.